Emcure launches Dapoxetine (Sustinex) for Premature Ejaculation


Premature Ejaculation (PE) is one of the commonly encountered male sexual disorder in clinical practice. The treatment options available for PE include counseling, behavioral therapy, topical therapies and systemic pharmacological agents.

Dapoxetine is the first compound specifically developed and approved for the treatment of PE in men of age 18-64. The recommended starting dose is 30 mg daily as needed 1-3 hours prior to sexual intercourse. The maximum recommended dose is 60 mg daily. Dapoxetine must be taken under medical supervision only.

Dapoxetine is an effective, safe and well tolerated treatment for PE and is likely to fulfill the treatment needs of most patients. At present Dapoxetine has the largest data base for use in men with PE and it is the only agent for which SSRI class related effects have been studied in PE population.

The most common adverse drug reactions reported during clinical trials were headache, dizziness, nausea, diarrhoea, insomnia and fatigue. The most common adverse events leading to discontinuation were nausea and dizziness. Medical advice is needed on how to use this product along with other medicines

Prescribing Information for Sustinex

Dapoxetine (Sustinex) is to be prescribed only by Urologists / Psychiatrists / Endocrinologists / Venerologists

For more information on Premature Ejaculation

Call Toll Free Helpline

1800 - 209 - 5121


Log on to